What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?

文化大學機構典藏 CCUR > 商學院 > 企業管理學系暨國際企業管理研究所 > 期刊論文 > Item 987654321/48895

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://irlib.pccu.edu.tw/handle/987654321/48895

题名:	What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?
作者:	Wang, WK (Wang, Wei-Kang) Lu, WM (Lu, Wen-Min) Kweh, QL (Kweh, Qian Long) Truong, HTN (Hoang Tu Nhi Truong)
贡献者:	國企系
关键词:	INTELLECTUAL PROPERTY-RIGHTS MARKET VALUE OPERATING PERFORMANCE CONTEXTUAL VARIABLES FIRM VALUE INNOVATION EFFICIENCY PRODUCTIVITY INVESTMENT IMPACT
日期:	2020-07
上传时间:	2020-12-11 15:21:09 (UTC+8)
摘要:	This paper investigates how patents and research and development (R&D) spikes affect the corporate performance of 863 firm-year observations of U.S. biopharmaceutical companies. First, a dynamic data envelopment analysis model is adopted to evaluate the performance of the U.S. biopharmaceutical companies. Then, ordinary least squares regression is used to explore the effects of three patent-related variables (patent counts, citations, and claims) and R&D spikes on corporate performance. This study finds positive impacts of patent counts, citations, and claims on corporate performance. In addition, the results show that R&D spikes have negative contemporaneous effects and time-lagged effects on corporate performance.
關聯:	MANAGERIAL AND DECISION ECONOMICS 卷冊: 41 期: 5 頁數: 762-770
显示于类别:	[企業管理學系暨國際企業管理研究所] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	137	检视/开启

检视Licence

在CCUR中所有的数据项都受到原著作权保护.